By Tom Rosenthal
Eravacycline (Xerava, Tetraphase Pharmaceuticals), a novel, fully synthetic fluorocycline antibiotic, demonstrated high clinical cure rates and favorable microbiological eradication response rates in adults with complicated intraabdominal infections (cIAIs), according to research presented at IDWeek 2018, in San Francisco.
Results from a pooled analysis of the two phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trials of eravacycline showed similar
NOVEMBER 12, 2018